Literature DB >> 27308637

Wingless/β-catenin signaling as a modulator of chemoresistance in cancer.

John Inge Johnsen1, Malin Wickström1, Ninib Baryawno2.   

Abstract

O6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme involved in chemoresistance. We have shown that MGMT abundance is regulated by canonical Wingless (Wnt) signaling and that inhibition of Wnt signaling restores chemosensitivity in preclinical cancer models. These findings have direct therapeutic implications for the treatment of cancers with high MGMT expression.

Entities:  

Keywords:  MGMT; chemoresistance; temozolomide; β-catenin

Year:  2016        PMID： 27308637      PMCID： PMC4905426          DOI： 10.1080/23723556.2015.1131356

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

Review 1.  MGMT: its role in cancer aetiology and cancer therapeutics.

Authors:  Stanton L Gerson
Journal:  Nat Rev Cancer       Date:  2004-04       Impact factor: 60.716

Review 2.  Wnt/β-catenin signaling and disease.

Authors:  Hans Clevers; Roel Nusse
Journal:  Cell       Date:  2012-06-08       Impact factor: 41.582

Review 3.  Can we safely target the WNT pathway?

Authors:  Michael Kahn
Journal:  Nat Rev Drug Discov       Date:  2014-07       Impact factor: 84.694

4.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.

Authors:  G Steinbach; P M Lynch; R K Phillips; M H Wallace; E Hawk; G B Gordon; N Wakabayashi; B Saunders; Y Shen; T Fujimura; L K Su; B Levin; L Godio; S Patterson; M A Rodriguez-Bigas; S L Jester; K L King; M Schumacher; J Abbruzzese; R N DuBois; W N Hittelman; S Zimmerman; J W Sherman; G Kelloff
Journal:  N Engl J Med       Date:  2000-06-29       Impact factor: 91.245

Review 5.  O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry.

Authors:  Markus Christmann; Barbara Verbeek; Wynand P Roos; Bernd Kaina
Journal:  Biochim Biophys Acta       Date:  2011-07-01

6.  An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis.

Authors:  Patrick M Lynch; Carol A Burke; Robin Phillips; Jeffrey S Morris; Rebecca Slack; Xuemei Wang; Jun Liu; Sherri Patterson; Frank A Sinicrope; Miguel A Rodriguez-Bigas; Elizabeth Half; Steffen Bulow; Andrew Latchford; Sue Clark; William A Ross; Bonnie Malone; Hennie Hasson; Ellen Richmond; Ernest Hawk
Journal:  Gut       Date:  2015-03-19       Impact factor: 23.059

Review 7.  Targeting O⁶-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy.

Authors:  Bernd Kaina; Geoffrey P Margison; Markus Christmann
Journal:  Cell Mol Life Sci       Date:  2010-08-18       Impact factor: 9.261

Review 8.  Molecular mechanisms of drug resistance.

Authors:  D B Longley; P G Johnston
Journal:  J Pathol       Date:  2005-01       Impact factor: 7.996

Review 9.  Cancer drug resistance: an evolving paradigm.

Authors:  Caitriona Holohan; Sandra Van Schaeybroeck; Daniel B Longley; Patrick G Johnston
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

10.  Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.

Authors:  Malin Wickström; Cecilia Dyberg; Jelena Milosevic; Christer Einvik; Raul Calero; Baldur Sveinbjörnsson; Emma Sandén; Anna Darabi; Peter Siesjö; Marcel Kool; Per Kogner; Ninib Baryawno; John Inge Johnsen
Journal:  Nat Commun       Date:  2015-11-25       Impact factor: 14.919
  10 in total
  4 in total

1.  Long noncoding RNA MEG3 suppresses liver cancer cells growth through inhibiting β-catenin by activating PKM2 and inactivating PTEN.

Authors:  Qidi Zheng; Zhuojia Lin; Jie Xu; Yanan Lu; Qiuyu Meng; Chen Wang; Yuxin Yang; Xiaoru Xin; Xiaonan Li; Hu Pu; Xin Gui; Tianming Li; Wujun Xiong; Dongdong Lu
Journal:  Cell Death Dis       Date:  2018-02-15       Impact factor: 8.469

Review 2.  The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling.

Authors:  Boris Y Shorning; Manisha S Dass; Matthew J Smalley; Helen B Pearson
Journal:  Int J Mol Sci       Date:  2020-06-25       Impact factor: 5.923

3.  Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.

Authors:  Francesca Lombardi; Francesca Rosaria Augello; Serena Artone; Mitilda Karoli Gugu; Maria Grazia Cifone; Benedetta Cinque; Paola Palumbo
Journal:  Int J Mol Sci       Date:  2022-01-28       Impact factor: 5.923

Review 4.  Unravelling the Role of Kinases That Underpin Androgen Signalling in Prostate Cancer.

Authors:  Katie Joanna Miller; Mohammad Asim
Journal:  Cells       Date:  2022-03-10       Impact factor: 6.600
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.